HRT Financial’s Pacira BioSciences PCRX Stock Holding History

HRT Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$415K	Sell	18,384 -98,011	-84%	-$2.18M	﹤0.01%	2662
2025 Q4	$3.01M	Buy	116,395 +7,936	+7%	+$189K	0.01%	1038
2025 Q3	$2.79M	Buy	+108,459	New	+$2.66M	0.01%	963
2025 Q2	–	Sell	-176,688	Closed	-$4.39M	–	3316
2025 Q1	$4.39M	Sell	176,688 -3,213	-2%	-$76.9K	0.03%	478
2024 Q4	$3.39M	Buy	+179,901	New	+$3.16M	0.02%	539
2023 Q2	–	Sell	-6,645	Closed	-$271K	–	3058
2023 Q1	$271K	Sell	6,645 -153,077	-96%	-$6.09M	﹤0.01%	1773
2022 Q4	$6.17M	Buy	159,722 +137,685	+625%	+$6.7M	0.09%	210
2022 Q3	$1.17M	Buy	+22,037	New	+$1.23M	0.01%	821
2021 Q4	–	Sell	-19,157	Closed	-$1.07M	–	3855
2021 Q3	$1.07M	Sell	19,157 -35,147	-65%	-$2.03M	0.01%	1204
2021 Q2	$3.29M	Buy	+54,304	New	+$3.44M	0.03%	417
2019 Q4	–	Sell	-7,938	Closed	-$302K	–	1519
2019 Q3	$302K	Buy	+7,938	New	+$317K	0.01%	940
2019 Q1	–	Sell	-7,866	Closed	-$338K	–	718
2018 Q4	$338K	Buy	+7,866	New	+$367K	0.05%	315

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial's PCRX Position: Q1 2026 in Review

HRT Financial reduced its Pacira BioSciences (PCRX) stake by 84% in Q1 2026, selling an estimated $2.18M and leaving 18,384 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

HRT Financial first reported a position in PCRX in Q4 2018 and has held it in 12 quarters since. The position peaked at $6.17M in Q4 2022. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

HRT Financial held 18,384 shares of Pacira BioSciences worth $415K as of Q1 2026.
HRT Financial sold 98,011 Pacira BioSciences shares in Q1 2026, an estimated $2.18M.
Pacira BioSciences made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2662 holding.
HRT Financial first reported a position in Pacira BioSciences in Q4 2018 and has held it in 12 quarters since.
HRT Financial's Pacira BioSciences position peaked at $6.17M in Q4 2022.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.